Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in jos, north-central Nigeria

Akinyemi O.D. Ofakunrin*, Edache S. Okpe, Tolulope O. Afolaranmi, Rasaq R. Olaosebikan, Patience U. Kanhu, Kehinde Adekola, Nantok Dami, Atiene S. Sagay

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Hydroxyurea is underutilized by sickle cell health-care providers in Nigeria despite available evidence of its effectiveness in reducing the manifestations and complications of sickle cell disease (SCD). Objectives: To assess the level of utilization and provider-related barriers to the use of hydroxyurea in SCD therapy in Jos, Nigeria. Methods: A cross-sectional study conducted among 132 medical doctors providing care for SCD patients. Data on so-cio-demographics, utilization and barriers to hydroxyurea use were obtained. The barriers were fed cumulatively into the logistic regression model as predictors of utilization. Results: Of the 132 care providers, 88 (67%) had been in medical practice for ≥6years. The level of utilization of hy-droxyurea was 24.2%. The significant barriers that predicted the non-utilization of hydroxyurea included lack of expertise (OR=5.1; 95% CI=2.65–9.05), lack of clinical guidelines (OR=3.84; 95% CI=2.37-14.33), fear of side-effects (OR=0.50; 95% CI=0.22–0.68) and doubt about its effectiveness (OR=0.30; 95% CI=0.20–0.90). Conclusion: The level of utilization of hydroxyurea in the treatment of SCD among the care providers is sub-optimal with the lack of expertise in its use identified as the most prominent barrier. There is an urgent need for the training of sickle cell care-providers and the development of clinical guidelines on hydroxyurea use.

Original languageEnglish (US)
Pages (from-to)765-774
Number of pages10
JournalAfrican Health Sciences
Volume21
Issue number2
DOIs
StatePublished - Jun 2021

Keywords

  • Barriers to hydroxyurea
  • Hydroxyurea utilization
  • Nigeria
  • Sickle cell disease

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in jos, north-central Nigeria'. Together they form a unique fingerprint.

Cite this